Recruiting PHASE4 INTERVENTIONAL 1-arm NCT07176689

Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

A Single-Arm, Open-Label Phase 4 Study of Nirogacestat in Adult Premenopausal Females With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)

Sponsor: SpringWorks Therapeutics, Inc.

Conditions Aggressive Fibromatosis Desmoid Tumor

Interventions Nirogacestat

Updated 5 times since 2025 Last updated: Mar 2, 2026 Started: Sep 17, 2025 Primary completion: Feb 28, 2031 Completion: Mar 30, 2031

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07176689, this PHASE4 trial focuses on Aggressive Fibromatosis and Desmoid Tumor and remains actively recruiting participants. Sponsored by SpringWorks Therapeutics, Inc., it has been updated 5 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE4
Feb 2026 — Mar 2026 [monthly]

Recruiting PHASE4
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE4
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE4
Oct 2025 — Dec 2025 [monthly]

Recruiting PHASE4

First recorded

Sep 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

SpringWorks Therapeutics, Inc.

Data source: SpringWorks Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Barcelona, Spain , Bologna, Italy , Brussels, Belgium , Cambridge, United Kingdom , Candiolo, Italy , Leiden, Netherlands , London, United Kingdom , Madrid, Spain , Manchester, United Kingdom and 6 more locations